Research

Recruitment for PPALM Study

Refer your patients with radiotherapy-induced bleeding

This randomised, double-blind, placebo-controlled, NIHR-approved trial is recruiting patients with new-onset rectal bleeding affecting quality of life and due to radiation-induced telangiectasia who are free of other abnormal GI symptoms.

For further details or to arrange referral contact:

Jennifer Matthews, trial coordinator
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: 0207 352 8171 ext. 1515

Recruitment deadline: 31 July 2016

Paediatric European Digestive Diseases Clinical Research Network – PEDDCReN

PEDDCReN was an exciting new initiative with the key aim of forming a clinical trials network to study (and ultimately provide) effective medicines for paediatric patients in the speciality of Gastroenterology, Hepatology and Nutrition. It was established with the support of LINK funding from the UEG and was led by the BSG in collaboration with various European societies and ENPR-EMA (The European Network of Paediatric Research at the European Medicines Agency). The project supported both industry and non-industry investigators in running high quality multi-centre clinical trials. The final report has now been published.

HCV clinical trial and tissue biobank

Professor Will Irving ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ) is chief investigator for an observational study (UKCRN 11582) of 10,000 patients with laboratory evidence of HCV infection, either past or current. Information about the study is included as 'Study of the Month' in the October NIHR Specialty Group newsletter. The aim is to develop a biobank, analyse the contribution of a range of host and viral factors to disease outcome, and determine the clinical utility of routine IL-28B genotyping in the management of HCV-infected patients in the UK. For further information please contact Professor Irving.

 

IBD Nixon Twin and Multiplex Registry

UK gastroenterologists are invited to refer concordant and discordant twin pairs, as well as families where three or more first degree relatives have an IBD diagnosis, to the twin/multiplex registry. We will collect epidemiological data and invite members to donate to a biobank. This will become a powerful research resource that will be available for research collaborations in the future. Further information about how to refer twins or families is available from Hannah Gordon, Senior Clinical Research Fellow (Gastroenterology), IBD Nixon TAM Registry Co-Investigator, Chelsea and Westminster Hospital, This e-mail address is being protected from spambots. You need JavaScript enabled to view it

BSG members win substantial funding for clinical trial

Several BSG members were co-applicants on a recent successful application for substantial funding of a clinical trial in hepatology. Prof Mark Thursz, Dr Steve Ryder, Prof Matthew Cramp, Dr Paul Richardson and Dr Stuart McPherson are among a group represented by Dr Alastair O’Brien. The group received £1.6 million from the Health Innovation Challenge Fund (joint Wellcome Trust and Department of Health) for ATTIRE (Albumin To prevenT Infection in chronic liveR failure).

The money will fund a multi-centre, clinical, phase II and phase III trial at 15 sites that will examine whether administration of albumin to patients admitted with decompensated liver failure, in order to increase plasma levels to near normal, will prevent hospital acquired infection. Dr O'Brien's local clinical research network (LCRN) will fund the research nurse costs (>£1million).

Over 100,000 patients are admitted to hospital every year with advanced liver cirrhosis; infection is their most common problem. Dr O’Brien and his team have shown that, in these patients, leukocyte function is markedly impaired by an up-regulation of the hormone Prostaglandin E2; infusion of albumin can reverse this process by binding and neutralising its effects. Albumin is widely considered by hepatologists to be beneficial in liver disease but no putative mechanism had been identified, so no consensus had developed for how to prescribe it. Dr O’Brien and colleagues aim to repurpose albumin as an immunity-restoring drug to improve leukocyte function in patients with advanced cirrhosis and therefore improve their ability to fight off infection. They hope to demonstrate that its use will lead to reduced rates of nosocomial infection and mortality and shorter hospital stays, thereby reducing health care costs.

Page 2 of 4